Austin N Kirschner, Bobby Koneru, Suzanne Russo, Tracy M Paul, Phillip Bennion, Samuel Jean-Baptiste, Christien Kluwe, Diane C Ling, Neil Newman, Kevin Pearlstein, Nick Scarcella, Stephen Schaff, Rebecca Senehi, Yasamin Sharifzadeh, Rahul Tendulkar, Austin Dove
{"title":"低剂量放疗治疗炎性关节周围疾病:美国镭学会(ARS)适当使用标准(AUC)。","authors":"Austin N Kirschner, Bobby Koneru, Suzanne Russo, Tracy M Paul, Phillip Bennion, Samuel Jean-Baptiste, Christien Kluwe, Diane C Ling, Neil Newman, Kevin Pearlstein, Nick Scarcella, Stephen Schaff, Rebecca Senehi, Yasamin Sharifzadeh, Rahul Tendulkar, Austin Dove","doi":"10.1097/COC.0000000000001371","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To summarize the current evidence for low-dose radiation therapy (LDRT) in the treatment of inflammatory periarticular disorders (PAD) (tendinitis, enthesitis, fasciitides, and bursitis), including patient selection, optimal RT technique, and associated risks.</p><p><strong>Methods: </strong>A systematic literature review was designed using the Population, Intervention, Comparator, Outcome, Timing, and Study Design (PICOTS) framework and was assessed using the Cochrane and PRISMA methodologies. Eligible studies included prospective and retrospective studies published between January 1, 1996, and January 1, 2026. Clinical variant cases were developed as examples to illustrate practical applications of consensus recommendations. RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options.</p><p><strong>Results: </strong>LDRT is considered an appropriate treatment as a second-line treatment of chronic plantar fasciitis refractory to other therapies. LDRT may be an appropriate second-line treatment for other types of chronic, refractory PAD not associated with tendon full-thickness tears. LDRT is not usually appropriate as first-line treatment for early-stage PAD or in cases with complete tendon tears.</p><p><strong>Conclusions: </strong>The level of evidence to support the use of LDRT for the treatment of inflammatory PAD is limited. Based on the available evidence, LDRT may be considered for second-line treatment in appropriately selected patients.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Low Dose Radiotherapy for the Treatment of Inflammatory Periarticular Disorders: An American Radium Society (ARS) Appropriate Use Criteria (AUC).\",\"authors\":\"Austin N Kirschner, Bobby Koneru, Suzanne Russo, Tracy M Paul, Phillip Bennion, Samuel Jean-Baptiste, Christien Kluwe, Diane C Ling, Neil Newman, Kevin Pearlstein, Nick Scarcella, Stephen Schaff, Rebecca Senehi, Yasamin Sharifzadeh, Rahul Tendulkar, Austin Dove\",\"doi\":\"10.1097/COC.0000000000001371\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To summarize the current evidence for low-dose radiation therapy (LDRT) in the treatment of inflammatory periarticular disorders (PAD) (tendinitis, enthesitis, fasciitides, and bursitis), including patient selection, optimal RT technique, and associated risks.</p><p><strong>Methods: </strong>A systematic literature review was designed using the Population, Intervention, Comparator, Outcome, Timing, and Study Design (PICOTS) framework and was assessed using the Cochrane and PRISMA methodologies. Eligible studies included prospective and retrospective studies published between January 1, 1996, and January 1, 2026. Clinical variant cases were developed as examples to illustrate practical applications of consensus recommendations. RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options.</p><p><strong>Results: </strong>LDRT is considered an appropriate treatment as a second-line treatment of chronic plantar fasciitis refractory to other therapies. LDRT may be an appropriate second-line treatment for other types of chronic, refractory PAD not associated with tendon full-thickness tears. LDRT is not usually appropriate as first-line treatment for early-stage PAD or in cases with complete tendon tears.</p><p><strong>Conclusions: </strong>The level of evidence to support the use of LDRT for the treatment of inflammatory PAD is limited. Based on the available evidence, LDRT may be considered for second-line treatment in appropriately selected patients.</p>\",\"PeriodicalId\":50812,\"journal\":{\"name\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2026-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000001371\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001371","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Low Dose Radiotherapy for the Treatment of Inflammatory Periarticular Disorders: An American Radium Society (ARS) Appropriate Use Criteria (AUC).
Objectives: To summarize the current evidence for low-dose radiation therapy (LDRT) in the treatment of inflammatory periarticular disorders (PAD) (tendinitis, enthesitis, fasciitides, and bursitis), including patient selection, optimal RT technique, and associated risks.
Methods: A systematic literature review was designed using the Population, Intervention, Comparator, Outcome, Timing, and Study Design (PICOTS) framework and was assessed using the Cochrane and PRISMA methodologies. Eligible studies included prospective and retrospective studies published between January 1, 1996, and January 1, 2026. Clinical variant cases were developed as examples to illustrate practical applications of consensus recommendations. RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options.
Results: LDRT is considered an appropriate treatment as a second-line treatment of chronic plantar fasciitis refractory to other therapies. LDRT may be an appropriate second-line treatment for other types of chronic, refractory PAD not associated with tendon full-thickness tears. LDRT is not usually appropriate as first-line treatment for early-stage PAD or in cases with complete tendon tears.
Conclusions: The level of evidence to support the use of LDRT for the treatment of inflammatory PAD is limited. Based on the available evidence, LDRT may be considered for second-line treatment in appropriately selected patients.
期刊介绍:
American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists.
The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles.
The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.